Tarsus files 8-K confirming closed terms of Alkeus acquisition and Stargardt drug rights
The filing details the $270 million upfront cash payment, stock issuance, and up to $350 million in milestone payments for gildeuretinol.
SEC filing
Latest
4 stories
Thursday, September 10
Thursday, August 6
Tarsus Pharmaceuticals prices $125 million private placement financing
The company said the oversubscribed PIPE deal drew existing Alkeus Pharmaceuticals investors after Tarsus announced its planned acquisition of Alkeus.
SEC filing
Tarsus posts record XDEMVY sales, raises guidance, moves to acquire Alkeus
Tarsus reported $173.9 million in second quarter XDEMVY sales and disclosed a pending acquisition of Alkeus Pharmaceuticals along with a $125 million private placement.
SEC filing
Monday, July 13
Tarsus Pharmaceuticals' chief commercial officer to depart July 15
Aziz Mottiwala is leaving the company to become CEO of a public medical device company, according to a filing dated July 13, 2026.
SEC filing